CI vs INDV: fair value comparison
The Cigna Group and Indivior Pharmaceuticals, Inc. · Updated 2026-09-07
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, INDV currently sits closer to the top of our discount ranking.
| CI | INDV | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $282.52 | $37.37 |
| 12-month range | $244.41–$289.26 | $23.46–$40.25 |
| Sector rank | #34 of 113 Healthcare | #30 of 113 Healthcare |
| Quality grade | F | F |
| Leverage | Moderate | Low |
| Margin trend | Contracting | Stable |
| Revenue growth | Strong | Modest |
| RSI zone | Neutral | Oversold |
| 50/200-day trend | — | Mixed |
| DCF cross-check | Undervalued | Overvalued |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: CI fair value analysis · INDV fair value analysis